NCT
HOME CURRENT ARCHIVE COVID-19
HOME CURRENT ARCHIVE PUBLISH INSTRUCTIONS
FOR AUTHORS COVID-19 LOG IN / REGISTER HISTORY ABOUT US DIRECTORY CONTACT
Determinants of pathogenicity in pandemic influenza virus in Mexico: viral factors associated with severity

Mejía-Nepomuceno, Fidencio; Martínez-Maldonado, Fernando; Pérez-Padilla, Rogelio; Vázquez-Pérez, Joel Armando





2018, Number 4

2018; 77 (4)






ABSTRACT

The influenza virus often causes seasonal infections and occasionally pandemics which increase the level morbidity and mortality of respiratory diseases in humans. The influenza virus is capable of adapting to several hosts while circulating in a normal and constant manner in aquatic birds, poultry, pigs, horses and humans. Interaction between different viral subtypes in these hosts can generate new variants. In addition, point mutations naturally occur in all genes of the virus, which may confer advantages to viral replication, adaptation and evasion of the immune system, and allow viral isolates the probability of being more pathogenic. Characterization of the determinants of pathogenicity, allow monitoring and detecting possible strains at an early stage that may pose a threat to the human population. This will also contribute to identify possible molecular changes in the influenza virus genome, and to correlate these changes to the virulence and pathogenicity of the virus.

KEYWORDS

Determinants of pathogenicity, influenza A H1N1pdm09, characterization.

REFERENCES

  1. Szewczyk B, Bieńkowska-Szewczyk K, Król E. Introduction to molecular biology of influenza a viruses. Acta Biochim Pol 2014;61(3):397-401.

  2. Medina RA, García-Sastre A. Influenza A viruses: new research developments. Nat Rev Microbiol 2011;9(8):590-603. doi: 10.1038/nrmicro2613.

  3. Wu Y, Wu Y, Tefsen B, Shi Y, Gao GF. Bat-derived influenza-like viruses H17N10 and H18N11. Trends Microbiol 2014;22(4):183-191. doi: 10.1016/j.tim.2014.01.110.

  4. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol Rev 1992;56(1):152-179.

  5. Tscherne DM, García-Sastre A. Virulence determinants of pandemic influenza viruses. J Clin Invest 2011;121(1):6-13. doi: 10.1172/JCI44947.

  6. Arias CF, Escalera-Zamudio M, Soto-Del Río Mde L, Cobián-Güemes AG, Isa P, López S. Molecular anatomy of 2009 influenza virus A (H1N1). Arch Med Res 2009;40(8):643-654. doi: 10.1016/j.arcmed.2009.10.007.

  7. Xu L, Bao L, Zhou J, et al. Genomic polymorphism of the pandemic A (H1N1) influenza viruses correlates with viral replication, virulence, and pathogenicity in vitro and in vivo. PloS One 2011;6(6):e20698. doi: 10.1371/journal.pone.0020698.

  8. Ilyushina NA, Khalenkov AM, Seiler JP, et al. Adaptation of pandemic H1N1 influenza viruses in mice. J Virol 2010;84(17):8607-8616. doi: 10.1128/JVI.00159-10.

  9. Stevens J, Corper AL, Basler CF, Taubenberger JK, Palese P, Wilson IA. Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science 2004;303(5665):1866-1870. doi: 10.1126/science.1093373.

  10. Vazquez-Perez JA, Isa P, Kobasa D, et al. A (H1N1) pdm09 HA D222 variants associated with severity and mortality in patients during a second wave in Mexico. Virol J 2013;10:41. doi: 10.1186/1743-422X-10-41.

  11. Kilander A, Rykkvin R, Dudman SG, Hungnes O. Observed association between the HA1 mutation D222G in the 2009 pandemic influenza A(H1N1) virus and severe clinical outcome, Norway 2009-2010. Euro Surveill 2010;15(9).pii: 19498.

  12. Hatta M, Gao P, Halfmann P, Kawaoka Y. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science 2001;293(5536):1840-1842. doi: 10.1126/science.1062882.

  13. Hatta M, Hatta Y, Kim JH, Watanabe S, et al. Growth of H5N1 influenza A viruses in the upper respiratory tracts of mice. PLoS Pathog 2007;3(10):1374-1379. doi.org/10.1371/journal.ppat.0030133.

  14. Mase M, Tanimura N, Imada T, Okamatsu M, Tsukamoto K, Yamaguchi S. Recent H5N1 avian influenza A virus increases rapidly in virulence to mice after a single passage in mice. J Gen Virol 2006;87(Pt 12):3655-3659. doi: 10.1099/vir.0.81843-0.

  15. Steel J, Lowen AC, Mubareka S, Palese P. Transmission of influenza virus in a mammalian host is increased by PB2 amino acids 627K or 627E/701N. PLoS Pathog 2009;5(1):e1000252. doi: 10.1371/journal.ppat.1000252.

  16. Gabriel G, Herwig A, Klenk HD. Interaction of polymerase subunit PB2 and NP with importin alpha1 is a determinant of host range of influenza A virus. PLoS Pathog 2008;4(2):e11. doi: 10.1371/journal.ppat.0040011.

  17. Mehle A, Doudna JA. Adaptive strategies of the influenza virus polymerase for replication in humans. Proc Natl Acad Sci U S A 2009;106(50):21312-21316. doi: 10.1073/pnas.0911915106.

  18. Conenello GM, Zamarin D, Perrone LA, Tumpey T, Palese P. A single mutation in the PB1-F2 of H5N1 (HK/97) and 1918 influenza A viruses contributes to increased virulence. PLoS Pathog 2007;3(10):1414-1421. doi: 10.1371/journal.ppat.0030141.

  19. Hai R, Schmolke M, Varga ZT, et al. PB1-F2 expression by the 2009 pandemic H1N1 influenza virus has minimal impact on virulence in animal models. J Virol 2010;84(9):4442-4450. doi: 10.1128/JVI.02717-09.

  20. Seo SH, Hoffmann E, Webster RG. Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. Nat Med 2002;8(9):950-954. doi: 10.1038/nm757.

  21. Twu KY, Kuo RL, Marklund J, Krug RM. The H5N1 influenza virus NS genes selected after 1998 enhance virus replication in mammalian cells. J Virol 2007;81(15):8112-8121. doi: 10.1128/JVI.00006-07.

  22. Hale BG, Steel J, Medina RA, et al. Inefficient control of host gene expression by the 2009 pandemic H1N1 influenza A virus NS1 protein. J Virol 2010;84(14):6909-6922. doi: 10.1128/JVI.00081-10.

  23. Ives JA, Carr JA, Mendel DB, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 2002;55(2):307-317.

  24. Pandemias anteriores I Influenza pandémica (influenza) | CDC. Fecha de consulta: 5 octubre, 2018. Accesible en: https://espanol.cdc.gov/enes/flu/pandemic-resources/basics/past-pandemics.html.

  25. Chen GW, Shih SR. Genomic signatures of influenza A pandemic (H1N1) 2009 virus. Emerg Infect Dis 2009;15(12):1897-1903. doi: 10.3201/eid1512.090845.

  26. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, et al.; INER Working Group on Influenza. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 2009;361(7):680-689. doi: 10.1056/NEJMoa0904252.

  27. Sarti E, Manuell-Lee G, Mosqueda JL, et al. [Influenza A H1N1 (2009): considerations at the time of declaring the end of the contingency in Mexico]. Rev Invest Clin 2010;62(4):289-298.

  28. WHO|Pandemic (H1N1) 2009-update 68. Access date: 2018 October 5. Available from: http://www.who.int/csr/don/2009_10_02/en/.

  29. Schrauwen EJ, de Graaf M, Herfst S, Rimmelzwaan GF, Osterhaus AD, Fouchier RA. Determinants of virulence of influenza A virus. Eur J Clin Microbiol Infect Dis 2014;33(4):479-490. doi: 10.1007/s10096-013-1984-8.

  30. Liu Y, Childs RA, Matrosovich T, et al. Altered receptor specificity and cell tropism of D222G hemagglutinin mutants isolated from fatal cases of pandemic A(H1N1) 2009 influenza virus. J Virol 2010;84(22):12069-12074. doi: 10.1128/JVI.01639-10.

  31. Goka EA, Vallely PJ, Mutton KJ, Klapper PE. Mutations associated with severity of the pandemic influenza A(H1N1)pdm09 in humans: a systematic review and meta-analysis of epidemiological evidence. Arch Virol 2014;159(12):3167-3183. doi: 10.1007/s00705-014-2179-z.

  32. Ruggiero T, De Rosa F, Cerutti F, et al. A(H1N1)pdm09 hemagglutinin D222G and D222N variants are frequently harbored by patients requiring extracorporeal membrane oxygenation and advanced respiratory assistance for severe A(H1N1)pdm09 infection. Influenza Other Respir Viruses 2013;7(6):1416-1426. doi: 10.1111/irv.12146.

  33. Wedde M, Wählisch S, Wolff T, Schweiger B. Predominance of HA-222D/G polymorphism in influenza A(H1N1)pdm09 viruses associated with fatal and severe outcomes recently circulating in Germany. PLoS One 2013;8(2):e57059. doi: 10.1371/journal.pone.0057059.

  34. Wu C, Cheng X, Wang X, et al. Clinical and molecular characteristics of the 2009 pandemic influenza H1N1 infection with severe or fatal disease from 2009 to 2011 in Shenzhen, China. J Med Virol 2013;85(3):405-412. doi: 10.1002/jmv.23295.

  35. Ledesma J, Pozo F, Pérez Ruiz M, et al.; Spanish Influenza Surveillance System (SISS). Substitutions in position 222 of haemagglutinin of pandemic influenza A (H1N1) 2009 viruses in Spain. J Clin Virol 2011;51(1):75-78. doi: 10.1016/j.jcv.2011.01.020.

  36. Ilyushina NA, Khalenkov AM, Seiler JP, et al. Adaptation of pandemic H1N1 influenza viruses in mice. J Virol 2010;84(17):8607-8616. doi: 10.1128/JVI.00159-10.

  37. Chutinimitkul S, Herfst S, Steel J, et al. Virulence-associated substitution D222G in the hemagglutinin of 2009 pandemic influenza A(H1N1) virus affects receptor binding. J Virol 2010;84(22):11802-11813. doi: 10.1128/JVI.01136-10.

  38. Charu V, Chowell G, Palacio-Mejia LS, et al. Mortality burden of the A/H1N1 pandemic in Mexico: a comparison of deaths and years of life lost to seasonal influenza. Clin Infect Dis 2011;53(10):985-993. doi: 10.1093/cid/cir644.

  39. de la Rosa-Zamboni D, Vázquez-Pérez JA, Avila-Ríos S, et al. Molecular characterization of the predominant influenza A(H1N1)pdm09 virus in Mexico, December 2011-February 2012. PloS One 2012;7(11): e50116. doi: 10.1371/journal.pone.0050116.

  40. Arellano-Llamas R, Alfaro-Ruiz L, Arriaga Canon C, et al. Molecular features of influenza A (H1N1)pdm09 prevalent in Mexico during winter seasons 2012-2014. PloS One 2017;12(7):e0180419. doi: 10.1371/journal.pone.0180419.

  41. Linderman SL, Chambers BS, Zost SJ, et al. Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013-2014 influenza season. Proc Natl Acad Sci USA 2014;111(44):15798-15803. doi: 10.1073/pnas.1409171111.

  42. WHO|Recommended composition of influenza virus vaccines for use in the 2017 southern hemisphere influenza season. Access date: 2018 September 24. Available from: http://www.who.int/influenza/vaccines/virus/recommendations/2017_south/en/.

  43. Allen JD, Ross TM. H3N2 influenza viruses in humans: Viral mechanisms, evolution, and evaluation. Hum Vaccin Immunother 2018;14(8):1840-1847. doi: 10.1080/21645515.2018.1462639.

  44. Melidou A, Gioula G, Exindari M, et al. Influenza A(H3N2) genetic variants in vaccinated patients in northern Greece. J Clin Virol 2017;94:29-32. doi: 10.1016/j.jcv.2017.07.003.

  45. Rondy M, El Omeiri N, Thompson MG, Levêque A, Moren A, Sullivan SG. Effectiveness of influenza vaccines in preventing severe influenza illness among adults: A systematic review and meta-analysis of test-negative design case-control studies. J Infect 2017;75(5):381-394. doi: 10.1016/j.jinf.2017.09.010.


2018, Number 4

2018; 77 (4)